Advertisement
Home »

Risk of severe Covid-19 in prevalent users of α-1 adrenergic receptor antagonists: a national case-control study of Medicare beneficiaries.

Jul 17, 2023

REFERENCES & ADDITIONAL READING

PubMed

ABOUT THE CONTRIBUTORS

  • David J Graham

    Center for Drug Evaluation and Research, US Food and Drug Administration. Electronic address: david.graham1@fda.hhs.gov.

    Hector S Izurieta

    Center for Biologics Evaluation and Research, US Food and Drug Administration.

    Di Zhang

    Center for Drug Evaluation and Research, US Food and Drug Administration.

    Armen Avagyan

    Acumen, LLC.

    Hai Lyu

    Acumen, LLC.

    Roger Wiederhorn

    Center for Drug Evaluation and Research, US Food and Drug Administration.

    Yun Lu

    Center for Biologics Evaluation and Research, US Food and Drug Administration.

    Andrew D Mosholder

    Center for Drug Evaluation and Research, US Food and Drug Administration.

    Elizabeth R Smith

    Acumen, LLC.

    Yueqin Zhao

    Center for Drug Evaluation and Research, US Food and Drug Administration.

    Shanlai Shangguan

    Acumen, LLC.

    Huei-Ting Tsai

    Center for Drug Evaluation and Research, US Food and Drug Administration.

    Dinci Pennap

    Center for Drug Evaluation and Research, US Food and Drug Administration.

    Alexander T Sandhu

    Acumen, LLC; Division of Cardiology, Department of Medicine, Stanford University.

    Michael Wernecke

    Acumen, LLC.

    Thomas E MaCurdy

    Acumen, LLC; Department of Economics, Stanford University.

    Jeffrey A Kelman

    Centers for Medicare & Medicaid Services.

    Richard A Forshee

    Center for Biologics Evaluation and Research, US Food and Drug Administration.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement